Cirmtuzumab inhibits expression of NF-κB and STAT3 target genes in the CLL cells of patients treated with cirmtuzumab in phase I clinical trial. (A) GSEA plots of NF-κB and STAT3 target genes on pretreatment vs paired postcirmtuzumab CLL cells at D28 of therapy (n = 3). Gene set size (Size), enrichment score, normalized ES (NES), and FDR q values are indicated. (B) Immunoblot and flow cytometry analysis of CLL cells isolated from patients before and after treatment with cirmtuzumab for phospho-p65 and phosphor-STAT3, respectively. (C) The paired concentrations of IL-6 in the plasma of patients before and after treatment with cirmtuzumab (n = 5).